Mylan gets FDA nod for 150 mg strength of generic Adoxa

June 8 (Reuters) - Mylan Laboratories Inc. MYL.N said it received final approval from U.S. regulators for the 150 milligram dose of its generic version of Par Pharmaceutical Cos. Inc.'s (PRX.N) antibiotic, marketed as Adoxa.

The product will be shipped immediately, the company said in a statement.

Mylan previously received approval and is marketing the 50 mg, 75 mg and 100 mg strengths of the tablets, generically known as doxycycline.

(Reporting by Varsha Tickoo in Bangalore)

((Editing by Himani Sarkar; Reuters Messaging: varsha.tickoo.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; )) Keywords: MYLAN FDA/PAR

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS3576